Reginster Jean-Yves, Bruyere Olivier, Henrotin Yves
Bone and Cartilage Metabolism Research Unit, University of Liège, CHU Centre-Ville, Policliniques L. Brull, Liège, Belgium.
J Rheumatol Suppl. 2003 Aug;67:14-20.
Several entities have been carefully investigated for the symptomatic and structural management of osteoarthritis (OA). The most compelling evidence of a potential for inhibiting the structural progression of OA has been obtained with glucosamine sulfate, while some preliminary results also suggest that other compounds could be used in the same indication. At any rate, several medications have clearly demonstrated a symptomatic action, mainly in OA of the lower limbs, including pain relief and improvement of functional disability. An important issue is that all conclusive studies with such chemical entities resulted from the use of prescription medicines and not over-the-counter or nutriceutical supplements.
针对骨关节炎（OA）的症状和结构管理，已经对多种药物进行了深入研究。硫酸葡萄糖胺在抑制OA结构进展方面具有最有力的潜在证据，而一些初步结果也表明其他化合物可用于相同适应症。无论如何，几种药物已明确显示出有症状缓解作用，主要用于下肢OA，包括缓解疼痛和改善功能障碍。一个重要问题是，所有关于此类化学实体的结论性研究均来自处方药的使用，而非非处方药或营养补充剂。
